https://dermaclaim.com/
The company has seen its turnover increase in the last six months and continues its business growth plan with the acquisition of new facilities.
10 of July of 2024
The Valencian dermo-cosmetic research laboratory, specialised in efficacy and functionality claims through in vitro tests and clinical studies, closed the first half of 2024 with a 38% increase in turnover, compared to 2023, reaching 513 projects carried out for 107 different clients and 787 samples analysed, since the start of the activity in October 2021.
During this first half of 2024, 57% of the turnover corresponded to studies on functional ingredients, while 43% corresponded to tests on final cosmetic products or oral nutraceuticals. It is also important to note that 82% of revenues came from international customers, while 18% came from Spanish customers.
In order to continue with its business growth plan, Dermaclaim has recently acquired new commercial premises of 660 square metres, in an area close to the current clinical facilities. In these new premises, the company will connect the 2 departments (laboratory and clinic), which until now have been separated in different locations. Construction is expected to start in the last quarter of 2024 and will last until the first quarter of 2025.
Dermaclaim Lab S.L. ®
+34 96 187 45 82
LIVE & HYBRID All you need to know about preclinical and clinical testing is at…
Abstract Background Oxidative stress is a significant factor in skin aging and pigmentation, which can be precipitated…
Remote prescribing of cosmetic injectables is set to be banned within weeks in a landmark…